NASDAQ · Biotechnology

AVIR (AVIR) Stock

$5.49 +2.62% NASDAQ: AVIR Healthcare

Valuation

MetricValue
Price$5.49
Market Cap$439.35M
P/E Ratio-2.13
P/B Ratio1.21
P/S Ratio0.00
EPS (TTM)$-1.94
52-Week High$6.45
52-Week Low$2.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-57.45%
ROA-50.16%
ROCE-65.82%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio7.78

Annual Financials (USD)

Metric20212022202320242025
Revenue$351.0M$0$0$0$0
Operating Profit$138.0M$-131.0M$-164.0M$-193.0M$-181.0M
Net Profit$121.0M$-116.0M$-136.0M$-168.0M$-158.0M
EPS$1.37$-1.39$-1.63$-2.00$-1.94
Op Margin39.4%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$773.0M$667.0M$595.0M$465.0M$315.0M
Total Liabilities$63.0M$26.0M$40.0M$26.0M$40.0M
Cash$764.0M$647.0M$144.0M$65.0M$96.0M
Borrowings$0$3.0M$2.0M$2.0M$1.0M

Latest News

Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment MT Newswires · Jul 14, 2026 Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus GlobeNewswire · Jul 14, 2026 Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America MT Newswires · Jun 25, 2026 Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus GlobeNewswire · Jun 25, 2026 Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know Zacks · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-87.0M$-121.0M$-85.0M$-135.0M$-132.0M
Investing Cash Flow$0$-457.0M$40.0M$56.0M$189.0M
Financing Cash Flow$0$0$0$0$-26.0M
Net Cash Flow$-86.0M$-576.0M$-45.0M$-79.0M$31.0M
Free Cash Flow$-87.0M$-123.0M$-85.0M$-135.0M$-132.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-43.89%
Quick Ratio7.89
Interest Coverage—
Return 1Y36.10%
Return 3Y33.80%
Return 5Y-78.78%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACHV $8.25 +3.90% -4.63 $846.94M 0.00%
ALLO $1.99 -0.75% -2.17 $685.13M 0.00%
ARCT $16.23 +9.93% -2.93 $461.16M 0.00%
ENTA $13.51 +1.35% -6.04 $392.85M 0.00%
HUMA $0.57 -5.15% -4.19 $95.83M 0.00%

About AVIR

AVIR is led by CEO Jean-Pierre Sommadossi, employs 56 people, headquartered in US, publicly traded since 2020.

AVIR stock trades at $5.49 with a market capitalization of $439.35M. The stock is valued at a price-to-earnings (P/E) ratio of -2.13, price-to-book of 1.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.78 and $6.45, and currently trades 14.9% below its 52-week high.

On profitability, AVIR generates a return on equity (ROE) of -57.45%, return on capital employed of -65.82%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides